摘要
目的:比较克拉霉素与阿奇霉素治疗小儿支原体肺炎的疗效与安全性。方法:将100例支原体肺炎患儿随机分为研究组和对照组各50例,研究组予克拉霉素分散片15 mg/(kg.d)连服5 d停2 d,对照组予阿奇霉素分散片10 mg/(kg.d)连服3 d停4 d,为1个疗程,未痊愈者追加1个疗程,对两组临床疗效和不良反应进行观察比较。结果:在干预后第1周末和第2周末,研究组疗效均与对照组相当(Z=-0.161和-0.489,P均>0.05);两组干预后症状体征评分均低于干预前(F组内=757.020,P=0.000),干预与时间存在交互效应(F交互=2.294,P=0.044),但无组间差别(F组间=0.301,P=0.584);在干预后第5天,研究组减分幅度大于对照组(t=2.300,P<0.05),其余各时点两组间比较差异无统计学意义(t=1.578、0.157、0.739和0.341,P>0.05)。两组间不良反应比较差异无统计学意义(χ2=0.208,P=0.648)。结论:克拉霉素治疗小儿支原体肺炎疗效确切,与阿奇霉素相当,且起效较快,安全性好。
We aimed to explore the situation of Borna disease virus（BDV） infection in Guizhou Province and its correlation with neurological disorders.Firstly Western blot methods were established to detect peripheral blood levels of BDV in 62 viral encephalitis（VE） patients,32 Parkinson disease（PD） patients,19 Guillain-Barre syndrome（GBS） patients,7 Multiple sclerosis（MS） patients,and 120 healthy people.Then statistical software was used to analysis the experimental results.Total of 8 cases of 120 patients with neurological disorders were found nucleoprotein（P40） antibody-positive and the positive rate was 6.7%（8/120）.Among the 8 samples,the positive rates of viral encephalitis patient,Parkinson disease patient,Guillain-Barre syndrome patient,and Multiple sclerosis patient were 6.45%（4/62）,6.25%（2/32）,5.26%（1/19）,and 14.29%（1/7）,respectively.The healthy people group was negative.The positive rate of P40 antibodies in neurological disorders patients was significantly higher than that in healthy people（P=0.038）.All the result illustrates the situation of BDV infection in Guizhou Province and suggests that BDV infection may relate to the occurrence of neurological disorders.
出处
《儿科药学杂志》
CAS
2012年第11期4-6,共3页
Journal of Pediatric Pharmacy
关键词
支原体
肺炎
克拉霉素
阿奇霉素
疗效
安全性
Mycoplasmal
Pneumonia
Clarithromycin
Azithromycin
Efficacy
Safety
